{"name":"Tetec AG","slug":"tetec-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NOVOCART® 3D plus","genericName":"NOVOCART® 3D plus","slug":"novocart-3d-plus","indication":"Symptomatic cartilage defects of the knee","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NOVOCART® Inject plus","genericName":"NOVOCART® Inject plus","slug":"novocart-inject-plus","indication":"Symptomatic articular cartilage defects of the knee","status":"phase_3"}]}],"pipeline":[{"name":"NOVOCART® 3D plus","genericName":"NOVOCART® 3D plus","slug":"novocart-3d-plus","phase":"phase_3","mechanism":"NOVOCART® 3D plus is an autologous chondrocyte implant that regenerates cartilage tissue by delivering the patient's own expanded cartilage cells into a defect site.","indications":["Symptomatic cartilage defects of the knee","Osteoarthritis of the knee"],"catalyst":""},{"name":"NOVOCART® Inject plus","genericName":"NOVOCART® Inject plus","slug":"novocart-inject-plus","phase":"phase_3","mechanism":"NOVOCART® Inject plus is an autologous chondrocyte implantation therapy that delivers cultured patient cartilage cells directly into cartilage defects to promote tissue regeneration.","indications":["Symptomatic articular cartilage defects of the knee"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQenMxb1Q0TEVSWW50TnlZNThEb0RTcmVwcjQ1elYzWGhrWDFwZTRQYVAyMjNhUmxhcEUxaVlwT1ZnMXhPN1E0T1cyN281NUpJbmFib3RRbjcwRnIwdVEteVlHRUdzSzhQamJkSWhka1NZdGlnYTREcUlDMDJPVXpDd1VCcWd4MXFXOG5xSnRHYmFBWDhPdjVWZUhid0pSRVdYTUN0Y1NBdGMyckc4MlUybGNR?oc=5","date":"2025-07-25","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025 - European Medicines A","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}